Cannabis Stock Gainers And Losers From May 1, 2025 - FLUENT (OTC:CNTMF), CNBX Pharmaceuticals (OTC:CNBX)

Maple Leaf Green World MGWFF shares closed up 83.67% at $0.03 Elixinol Wellness ELLXF shares closed up 77.11% at $0.01 4Front Ventures FFNTF shares closed up 45.00% at $0.00 1933 Industries TGIFF shares closed up 42.86% at $0.01 SOL Global Investments SOLCF shares closed up 19.84% at $0.09

Original reporting
Benzinga · Benzinga Insights
Published May 1, 2025, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 2, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CNBX
Bullish
medium confidence
Mentioned
$CNBX · $CRBP
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$CNBXBullishMed
01

Why it matters

The recent gains across multiple tickers suggest increased investor confidence, possibly influenced by industry developments or favorable regulatory news.

02

Market read

The sector is currently experiencing bullish momentum, with multiple companies showing significant share price increases, indicating a positive short-term trading environment.

03

What to watch

Regulatory changes, market saturation, or macroeconomic factors could impact the sustainability of current bullish trends; technical indicators and broader market conditions should be monitored.

Relevance 6/10Timing: Short-term, within days to weeks

Background

The cannabis industry has experienced significant volatility and growth, with recent positive news and market sentiment driving share price surges.

Company-level read

Ticker impact

$CNBXBullishMedium confidence
Context

High relevance due to recent gains and inclusion in the top gainers list.

Expected impact

Possible continuation of upward trend in the near term.

Evidence & confidence

Strong recent gains and bullish sentiment support further movement, but technical confirmation needed.

$CRBPBullishLow confidence
Context

Low relevance with a 19.90% relevance score; minimal impact on overall market sentiment.

Expected impact

Likely minimal impact on broader market; focus on more relevant tickers.

Evidence & confidence

Lower relevance suggests limited market influence; technical analysis required for actionable insights.

Market effects

Positive sentiment in cannabis sector may boost related industries such as retail, manufacturing, and life sciences

Potential uplift in North American cannabis markets, especially in regions with legal reforms

Limited; primarily regional effects with some influence on global cannabis industry sentiment

Counterpoint

The recent gains may be driven by speculative trading or short-term hype, risking a correction or pullback in the near future.

Key entities

  • Maple Leaf Green World

    Cannabis cultivation and production company.

  • Elixinol Wellness

    CBD and wellness product manufacturer.

  • 4Front Ventures

    Cannabis retailer and producer.

  • 1933 Industries

    Cannabis consumer products.

  • SOL Global Investments

    Invests in cannabis and related industries.

Related articles

$CRBPMed

Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update o Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer o Reported topline data from the CANYON-1 Phase

$CRBPMedAI 9/10

Corbus Obesity Pill Shows 5% Weight Loss With Clean Safety Profile in Mid-Stage Trial — BigGo Finance

Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.

$CRBPMedAI 8/10

Obesity drug could have fewer side effects than GLP-1s

Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development